Considering the recently stated suggestion of neovascularization being implicated in myelodysplastic syndromes (MDS) pathogenesis, we evaluated multiple morphometric microvascular characteristics in MDS, in relation to clinicopathologic factors and prognosis. Trephines from 50 newly diagnosed MDS patients were immunostained for factor VIII and compared to those from 20 controls, 10 chronic myelomonocytic leukemia (CMML) and 12 acute myeloid leukemia (AML) patients. Quantitation of microvessel density (MVD), area, total vascular area (TVA), major and minor axis length, perimeter, compactness, shape factor, Feret diameter, and the number of branching vessels was performed by image analysis. Overall, the MDS group had significantly higher MVD, TVA, minor axis and shape factor values and significantly lower compactness than the control group. AML was characterized by increased vascularity compared to MDS and CMML, as well as by the presence of flattened microvessels (lower values of shape factor). Hypercellular MDS showed higher MVD. RA/RARS displayed larger caliber vessels than RAEB, which explains the favorable prognostic effect of increased size-related parameters on progression and/or survival. Moreover, decreased compactness and MVD were independent predictors of longer progression-free survival. It is concluded that angiogenesis is involved in the conversion of normal marrow to MDS and ultimately to AML and that disease progression within MDS is accompanied by qualitative alterations of the microvascular network. Furthermore, size-related parameters affect survival, while shape-related parameters and MVD are more influential with regard to progression-free survival. Leukemia (2001Leukemia ( ) 15, 1369Leukemia ( -1376 
Introduction
Angiogenesis entails the sprouting of new vessels from preexisting vasculature. Initiation of this process is fundamental not only to prenatal and postnatal tissue development, reproduction and wound healing, 1 but also to the growth of tumors beyond volumes so small that they can be fed and drained by diffusion only. 2 It is believed that the switch to the angiogenic phenotype in an early tumor is governed by a change in the dynamic balance of inducers and inhibitors of angiogenesis. These factors can be released from tumor cells and recruited host cells, usually in response to alterations in the immediate microenvironment (eg hypoxia). 3 One of the newer generations of prognostic factors in solid tumors that has attracted growing attention over recent years is tumor angiogenesis as reflected by microvessel counts determined on sections immunostained for vascular endothelial cell markers. The presumption is that enumeration of the number of microvessels within and around a tumor provides an estimate of the angiogenic capability of tumor cells, which in turn reflects the likelihood of invasion and metastasis. 4 This contention was verified on multiple occasions for a variety of malignancies. [5] [6] [7] [8] [9] Correspondence: P Korkolopoulou, 73 Vassileos Pavlou str, GR-154 52 P Psychico-Athens, Greece; Fax: 30 Although the evidence in support of angiogenesis as an indicator of higher malignant potential in solid tumors is indisputable, the clinical significance of this phenomenon in most hematologic malignancies is at this time an unresolved issue. However, there is accumulating evidence indirectly implicating angiogenesis in the pathophysiology and course of some leukemias and lymphoproliferative disorders. Thus, in multiple myeloma, bone marrow neovascularization has been proven to correlate with disease activity 10 and in B cell nonHodgkin's lymphomas with clinical stage. 11 An increased microvessel density (MVD) has also been documented in the bone marrows of patients with acute lymphoblastic leukemia (ALL), 12 chronic myeloid leukemia 13 and acute myeloid leukemia (AML).
14 Moreover, intracellular levels of vascular endothelial growth factor (VEGF) -a potent angiogenic molecule, are reportedly of prognostic significance in AML 15 and chronic lymphocytic leukemia. 16 The issue of angiogenesis in myelodysplastic syndromes (MDS) has been dealt with in two recent reports 13, 17 providing evidence of increased MVD in the bone marrows of these patients.
To our knowledge, this study is the first in the literature to evaluate multiple morphometric microvascular characteristics, besides MVD, in diferent types of MDS, in relation to clinicopathologic parameters and survival. Such information might prove valuable in clarifying certain steps in the evolution of the disease and would broaden our understanding of the clinical significance of angiogenesis in these patients.
Materials and methods

Patients
Bone marrow paraffin-embedded biopsies obtained at diagnosis from 50 patients with MDS during the years 1984 to 1997 were studied. Control marrows from 20 subjects with no evidence of marrow disease, performed for diagnostic purposes as part of staging procedure for Hodgkin's disease (13 cases), non-Hodgkin's lymphomas (five cases) and solid tumors (two cases), were also evaluated. In addition, we examined trephines from 12 cases of AML developing from pre-existing MDS. AML and control cases were age-and sexmatched with MDS cases. Diagnosis and FAB classification were established according to the principles laid down in the latest WHO classification. 18 Classification according to FAB criteria was established and confirmed by three hematologists independently. There were 28 males and 22 females with a median age of 67 years (range, 32-86). The frequency of MDS subtypes was RA 30 cases, RARS six cases and RAEB (5-19% blasts) 14 cases. Despite the fact that chronic myelomonocytic leukemia (CMML) has recently been removed from MDS, we also included 10 cases of CMML in our investigation to examine possible differences between CMML and MDS subtypes.
Enlargement of the spleen and liver was found in seven patients and of the spleen only in two, while 41 patients had no abnormal findings. The results of the blood tests are shown in Table 1 . For purposes of statistical analysis of the correlations between clinical-laboratory parameters and microvessel parameters the following categorizations were made. Bone marrow cellularity was considered increased (Ͼ75%), decreased (Ͻ25%) or normal (Ͼ25%, Ͻ75%), as evaluated by two experienced hematopathologists. According to the International Prognostic Score System (IPSS) proposed by Greenberg et al, 19 cytogenetic abnormalities were assigned into three groups: good prognosis (27 patients, 54%), intermediate prognosis (two patients, 4%) and poor prognosis (seven patients, 14%). Cytogenetic data were missing in 14 patients. Hemoglobin levels, white blood cell count, polymorphonuclear count and platelet count were categorized as increased, normal or decreased (Table 1) . Treatment consisted of supportive care with administration of erythropoietin and/or granulocyte colony-stimulating factor (G-CSF), and transfusions as needed. During a median (range) follow-up period of 26.5 (6-159) months, 11 (22%) patients progressed to AML. By the time that this study was undertaken, 27 (54%) patients had died from disease-related causes, whereas the median (range) follow-up for the remaining 23 patients was 42 (6-159) months.
Immunohistochemical staining
Bone marrow specimens were fixed in buffered formalin, decalcified with EDTA/HCl and embedded in paraffin. Serial sections (4 m thick) of each sample were processed for immunohistochemical identification of microvascular endothelial cells with a rabbit polyclonal antibody against factor VIII (Dako, Carpinteria, CA, USA). The antibody was applied at a dilution of 1:150 for 1 h. Before staining, slides were incubated four times for 5 min in citrate buffer pH 6.0, at 750 W, in a microwave oven. 20 Application of the primary antibody was followed by the standard three-step streptavidin peroxidase technique. 21 All specimens were treated using identical procedures. Negative controls (ie sections in which the primary antibody was substituted with non-immune rabbit serum) were also stained in each run.
Microvessel counting and image analysis
Immunohistochemically stained slides for factor VIII were examined using a Zeiss Axiolab microscope (Carl Zeiss Jena, Jena, Germany) with a mechanical stage. According to Padro et al, 14 to identify the area showing the most intense vascularization (ie the 'hot spot'), the entire bone marrow section was simultaneously scanned, field per field, by two experienced investigators at ×100 magnification. The selection of hot spot was based on observing restricted areas within a ×100 field with an impression of a higher density of factor VIII positive single endothelial cells or clusters of endothelial cells. The magnification was then changed to ×250 and the investigators were allowed to reposition the slide until the highest number of microvessels was included within the ×250 field. This area was defined as the 'hot spot'. 22 These vascular 'hot spots' were suitable for analysis provided they were within cellular areas of the marrow (bone labellae, fat and connective tissue were excluded). The hot spot was photographed and printed on high quality photographic paper. Photographs were scanned by a Hewlett Packard ScanJet 3400C (Hewlett Packard, Palo Alto, CA, USA) to become digital and were stored as BMP file (1480 × 1070 pixels, 16.7 million colors (24-bit)). The whole system was calibrated with the use of a micrometer scale. In cases in which the most vascularized area was not obvious by visual impression, two to four optical fields with the highest density of capillaries and small vessels were photographed, though only the one with the highest MVD was finally taken into account for further evaluation. Conforming to published consensus 14, 23 any brown-stained endothelial cell or cluster, with or without a lumen, that was clearly separated from adjacent microvessels and other bone marrow cells was considered as a single, countable microvessel. The presence of blood cells or fibrin without any detectable endothelial cells was not sufficient to define a microvessel. Vessels with muscular walls were not counted; however there was no restriction regarding the size of the countable vessels, so as not to underestimate longitudinal sections or bifurcations of microvessels. 8 In addition to endothelial cells, megakaryocytes were also strongly positive for factor VIII. These cells were easily recognized by their characteristic size and morphology and served as internal controls to verify the adequacy of staining.
Quantification on digital images was performed by one investigator by using the Image Sigma Scan Software (Jandel Scientific, Erkrath, Germany) on a Pentium II personal computer. For each countable microvessel the outline was identified and traced ( Figure 1 ) and the following morphometric parameters were estimated: major axis length (the distance between the two points along the vessel periphery that are furthest apart), minor axis length (the longest axis perpendicular to major axis formed by two points along the vessel periphery), perimeter, area, compactness (perimeter 2 /area), shape factor (4 × area/perimeter 2 ) and Feret diameter √4 × area/. 24 The variables entered into the statistical analy-
Figure 1
Immunohistochemical staining of bone marrow endothelial cells for factor VIII in a case of MDS. The outline of each vessel is traced; the red layer represents the section area of each vessel. The yellow lines correspond to major and minor axis of each microvessel. Arrows point towards branching vessels (×250).
sis were the mean values of the above seven morphologic indices, the total count of microvessels per optical field (MVD), as well as the total area occupied by them (total vascular area, TVA) and the number of vascular ramifications per 100 vessel sections, as an expression of the complexity of the microvascular network. These points, at which a new branch emerged from a parent vessel, were recognized on the histological sections as Y-shaped, T-shaped or E-shaped. 8 The whole procedure took place without any knowledge of the patients' data. To confirm that the above counting technique was representative of bone marrow angiogenesis, we performed additional analysis in 10 randomly selected MDS cases. In these cases, we counted the microvessels in three random fields ×250.
Statistical analysis
Intrarater and interrater reliability were assessed by Pearson's correlation coefficient in 10 randomly selected cases. Concerning the interobserver variability the correlation coefficient was satisfactory for all the examined parameters (0.90 р r р 0.97, Figure 2a) . The same applied for the intraobserver variability (0.91рrр0.96). Reproducibility of measurements of the same optical field or of the same individual vessel was examined by the coefficient of variation between repeated measurements. The reliability coefficient ranged fom 0.8% to 4.1%. Furthermore, the MVD in the hot spot strongly correlated with the mean MVD of the three examined fields (r = 0.875, Figure 2b) . The same applied to the remaining microvascular parameters (0.84 р r р 0.90). The normality of distributions was tested with the Kolmogorov-Smirnov test. Differences in the values of microvascular parameters between groups were examined by the Mann-Whitney U-test. For the analysis of variance we used Kruskal-Wallis test. Spearman's rank correlation coefficient was calculated to determine associations between numerical variables.
Survival analysis was carried out in the entire cohort, as well as for RA/RARS and RAEB groups separately. The effect of various parameters (age, gender, bone marrow karyotype, FAB subtype, marrow cellularity, clinical and laboratory findings, and the microvascular parameters) on clinical outcome (progression to AML or death) was assessed by plotting survival curves according to the Kaplan-Meier method and groups were compared using the log-rank test. Age was categorized on the basis of the median value. Microvascular parameters were categorized on the basis of median value rounded at its nearest 10%. Multivariate analysis was performed using the stepwise Cox's regression model to evaluate the predictive power of each variable independently of the others. Numerical variables (age and the microvascular parameters) were entered in the analysis in continuous form, in order to avoid any 'data-driven' categorization. Statistical analysis was performed using the SPSS for Windows Software (SPSS, Chicago, IL, USA) on an IBM compatible computer. Differences were considered statistically significant when P-value (two-sided) was р0.05.
Results
Comparison of morphometric variables among MDS, control and AML groups
As shown in Table 2 , many angiogenic parameters, except compactness, were higher in MDS than in controls, although
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Figure 2
Graphs illustrating (a) the correlation between two independent observers regarding the measurement of area in 10 randomly selected MDS cases; and (b) the correlation between the microvessel count in hot spot and the mean microvessel count in three randomly selected fields. a statistically significant difference with Mann-Whitney U-test could only be attained by MVD (P Ͻ 0.001), TVA (P = 0.001), minor axis length (P = 0.013), compactness (P = 0.002) and shape factor (P Ͻ 0.001). Likewise, CMML cases exhibited higher values of shape factor (P = 0.013) and lower values of compactness (P = 0.025) than controls. Controls also showed a lesser degree of vessel branching compared to MDS (P = 0.034) and CMML (P = 0.048). These differences translated to a large number of large caliber, often arborizing vessels, the sections of which had a rounder shape in MDS bone marrow, compared with few simple, straight, flattened microvessels in controls (Figures 3-5) .
AML bone marrows were characterized by increased vascularity compared to MDS and CMML, not only in terms of MVD, but also with regard to size-related parameters (area, TVA, minor axis length, major axis length, perimeter, Feret diameter/for all associations, P Ͻ 0.001, Mann-Whitney Utest). However, shape factor tended to be lower in AML than in MDS and CMML (P Ͻ 0.001 and P = 0.004, respectively) as evidenced by the presence of flattened vessel sections (Figures 3-5) . As expected, compactness tended to be higher in AML than in MDS, although it did not quite reach statistical significance (P = 0.099). Interestingly, in none of the AML bone marrows we examined have we observed arborization (P = 0.006 for MDS and P = 0.007 for CMML). 
Figure 4
Microvessel caliber represented by total vascular area (TVA) and minor axis length, in controls, AML, MDS of various subtypes and CMML. Vessel caliber increases from controls through MDS and CMML to AML, but decreases from RA/RARS to RAEB.
Association of morphometric variables with clinicopathologic characteristics in MDS
None of the morphometric variables was related to patients' age, gender, chromosome abnormality, hepatosplenomegaly or hemoglobin level (for all P Ͼ 0.10, Mann-Whitney U-test). Bone marrows from patients with lower polymorphonuclear Shape factor values in controls, AML, MDS of various subtypes and CMML. Shape factor is increased in MDS and CMML, compared with controls and AML, but remains unaffected among FAB subtypes.
blood counts tended to show higher degree of vessel branching (median 17, range 0-57) in relation to the remaining ones (median 0, range 0-80; Mann-Whitney U-test, P = 0.004). Also, lower platelet counts were associated with lower values of shape factor and higher values of compactness (MannWhitney U-test, P = 0.031 and P = 0.018, respectively). A statistically significant relationship existed between MVD and cellularity in the sense that hypercellular MDS displayed higher MVD values than hypo-or normocellular ones (Kruskal-Wallis test, P = 0.047). The only angiogenic parameter correlated with MDS type was minor axis length (Mann-Whitney U-test, P = 0.041) (Table 3) . Thus, RA and RARS displayed larger caliber vessels than RAEB (Figures 3-5) . However, there was no difference between CMML and MDS subtypes (Mann-Whitney U-test, P Ͼ 0.10).
Correlations among the various morphometric variables in MDS
It is to be noted that a negative (though not strong) correlation existed between vessel number and vessel size parameters, such as area, major axis length and perimeter, evidenced by the presence of cases with relatively many but delicate microvessels on the one end of the spectrum and cases with few but larger caliber vessels on the other. 
Prognostic relevance of morphometric variables in MDS
To investigate whether bone marrow angiogenesis at diagnosis may predict progression of MDS to AML, we examined the impact of the microvascular parameters on time to progression. In univariate analysis, perimeter and minor axis length along with MDS type and platelet count were the only parameters affecting time to progression (Table 4) . Higher values of perimeter and minor axis length, as well as RA/RARS type and normal platelet count portended an increased pro- Leukemia gression-free survival ( Figure 6 ). When progression in relation to microvascular parameters was examined separately for RA/RARS and RAEB groups, increased values of minor axis length were linked to a lower probability of progression in RA/RARS patients. None of the examined microvascular parameters was significantly associated with progression in the RAEB group (Table 5 ). Multivariate analysis in the entire cohort indicated that time to progression was independently affected by MVD, FAB subtype and compactness ( Table 6 ).
As evidenced from the values of relative risk in Cox's model,
Figure 6
Progression-free survival in relation to (a) area, and (b) minor axis length (Kaplan-Meier curves).
Table 5
Evaluated vascular morphometric parameters in relation to overall and progression-free survival, for patients with RA/RARS and RAEB
Survival
Progression increased MVD and increased compactness adversely affected progression-free survival. With regard to survival, univariate analysis identified eight significant parameters, namely TVA, minor axis length, perimeter, Feret diameter, MDS type, karyotype, age and platelet count. Again, older patients having RA or RARS and displaying good prognosis karyotype, normal platelet count and increased values of size-related parameters tended to fare better ( Figure 7) . Large vessel sections, indicated by increased values of area, major axis length and Feret diameter, were also a favorable indicator in RAEB. By contrast, none of the microvascular parameters affected survival in RA/RARS (Table 5 ). Cox's model in the entire cohort selected only minor axis length, the age of the patient at diagnosis and platelet count (Table 6 ).
Discussion
The normal vascular bed in bone marrow consists of a complex anastomosing hexagonal network of sinusoids, analogous to that of kidney and spleen. 25 The close interdependence between the bone marrow vessels and the islands of hematopoietic cells has long been appreciated. 26 Recently, interest in bone marrow vascularity has revived owing to the demonstration of hematopoietic growth factor (ie stem cell factor and GM-CSF) production by endothelial cells. 27, 28 Under normal conditions, many of these capillaries and sinusoids are non- Table 6 Cox's proportional hazard estimation of overall and progression-free survival 
Figure 7
Overall survival in relation to (a) minor axis length, and (b) Feret diameter (Kaplan-Meier curves). patent and functionally dormant, and their endothelium may be non-reactive to endothelial markers, 29 accounting for the sparse MVD in control bone marrows. [12] [13] [14] 26 The present investigation has demonstrated that MDS has intermediate bone marrow vessel counts between controls and AML, confirming and extending the data recently reported by two independent groups of investigators. 13, 17 The analysis of various morphometric variables has further enabled us to substantiate a morphologic variability of the vascular pattern among controls, MDS, CMML and AML. Size-related parameters were highest among AML samples, but round vessel sections (manifested by increased values of shape factor and lower values of compactness), as well as arborization presented a peak in MDS and CMML. The overall impression gained from these findings is that bone marrow in MDS is characterized by a complex, often disorderly, vascular network, leading to retarded blood flow and, consequently, to a rise in intraluminal pressure (according to Bernulli's law). Then, coincident with the evolution towards AML, there is a marked increase in metabolic demands, which is to be met by excess blood flow. This is followed by an increase in vessel size and number and a decline in intraluminal pressure resulting in the plethora of flattened vessel sections encountered in AML samples. Analogous observations have recently been made in colorectal carcinomas. 8 In accordance with Aguayo et al, 13 MVD remained unaffected among MDS subtypes, but the RA/RARS group displayed significantly larger vessel sections than RAEB resulting in higher minor axis length values. The higher MVD values recorded by Pruneri et al 17 are obviously attributable to the inclusion of RAEB-t cases (which would currently be designated AML 18 ), along with RAEB and CMML. Based upon our findings, an attractive scenario could be that angiogenesis is initiated in the RA/RARS group as an outburst in the formation of wide sinusoidal spaces, 30 a step which might require more persistent VEGF receptor activation. 31 Then, the vessel caliber appears to be gradually restricted in relation to the disproportionate increase in dysplastic hemopoiesis, while the rate of new vessel formation is maintained. These qualitative changes in the vascular pattern as the disease progresses are further illustrated in the correlation of neutropenia with increased arborization of vessels and of thrombocytopenia with low shape factor observed in our study.
It could be argued that the elevated vessel counts recorded in MDS may be attributable to reactivation of preexisting marrow sinusoid endothelium for factor VIII. 29 However, the highly variable morphology of the microvessels with arborizing branching, the presence of endothelial sprouts without discernible lumina and the presence of hot spots, all speak in favor of a truly neoangiogenic phenomenon. The mechanisms responsible for neovascularization in MDS remain to be fully elucidated. However, the excessive production of angiogenic factors should obviously be considered a strong candidate. Bellamy et al 32 showed that foci of abnormal localized immature myeloid precursors coexpress VEGF and its receptor Flt-1 (VEGFR-1). Consistent with these data, Fiedler et al 28 documented VEGF mRNA and protein generation from AML blasts. Interestingly, increased levels of VEGF have been reported in the plasma, 13 as well as in bone marrow megakaryocytes 16 in MDS patients. Taken together, these data point towards a direct effect exerted by angiogenic factors on marrow vascularity, as well as on myeloid blasts in MDS. The negative correlation between MVD and size-related morphometric parameters might be indicative of the participation of the recently described intussusceptive mechanism of neovascular growth in the remodeling of microvascular network under the influence of intravascular blood flow patterns. 33 In our study, hypercellular MDS displayed elevated microvessel counts, introducing an element of doubt into the postulated absence of relationship between vascularity and cellularity. 13, 17 Of course, cellularity is unlikely to be the only factor responsible for increased angiogenesis in MDS, for reactive hypercellular bone marrows had MVD values comparable to those of their normocellular counterparts. The abovementioned discrepancy could be attributable to methodological differences, such as highest vs average vessel count, size and number of the fields and different antibodies (factor VIII, CD31, CD34). We chose to highlight vessels in our cases with factor VIII because of the frequently strong expression of CD31 or CD34 antigens on myeloid blasts.
14,17 Selection of hot spot for the study of angiogenesis has been adopted as Leukemia a standard procedure in solid neoplasms, but also in some hematological oncology studies. 14, 23, 34 It is also worthy of note, that according to Padro et al 14 and our findings, microvessel counting using hot spots is truly representative of the total degree of angiogenesis in the bone marrow samples.
To the best of our knowledge, the current study is the first to deal with the impact of angiogenesis on the progression and clinical outcome of patients with MDS. The results of survival analysis recapitulate most of the factors that have been advanced as potentially important determinants of clinical outcome in MDS patients, namely the FAB subtype, the bone marrow karyotype, the degree of cytopenia and the age of the patient, 19 advocating that our cohort was quite representative and that statistical analysis was valid. The higher survival rates and the lower progression probability assigned to those cases with high values of size-related parameters are largely a reflection of the fact that the mean vessel size is increased in the prognostically more favorable group of RA and RARS. Accordingly, the adverse effect of increased values of MVD and compactness in terms of progression, indicated by the results of multivariate analysis, obviously relates to the increased vascularity and to the prevalence of flattened vascular pattern in AML, respectively. Following this line of argument, we could hypothesize that those MDS, whose bone marrows present a large number of microvessels of this type, are endowed with a nutritional advantage, allowing their earlier progression to AML. In alignment with these findings, MVD has also been proposed as a new prognostic factor in multiple myeloma. 35 Current treatment of MDS remains problematic, with the majority of patients receiving supportive and symptomatic palliative treatment. Therefore, better therapies are urgently needed for both low and high risk patients. Several anti-angiogenic compounds are being evaluated in clinical trials. Results from these studies indicate that anti-angiogenic therapy is highly promising in certain hematologic neoplastic diseases such as multiple myeloma 36 and myelofibrosis, 37 inhibiting neoplastic growth by a mechanism of 'tumor stabilization'. 38 Most recently, Raza et al 39 have administered thalidomide in a small number of MDS patients and observed that half of them became transfusion-independent. Given these encouraging preliminary results and in view of our observation that increased MVD is indepedently linked to earlier progression to AML, anti-angiogenic therapy certainly warrants a trial in larger number of patients with MDS. 40 In summary, our data support the concept that the generation of new vessels is mandatory to the multistep process of conversion of normal bone marrow to MDS and ultimately to AML. However, disease progression within MDS is accompanied by qualitative, rather than quantitative alterations of the microvascular network, emphasizing the need for a multiparameter approach to the phenomenon of angiogenesis in MDS. More importantly, our study demonstrates that the prognostic significance of angiogenesis in terms of patient survival is better assessed by size-related morphometric parameters, whereas MVD and microvessel shape become influential with regard to progression to leukemia. While of obvious biologic interest, the clinical worth of counting microvessels in the bone marrows from MDS should await validation in prospective clinical studies with a larger number of patients. The same applies to the potential value of antiangiogenic therapy in delaying or even preventing disease progression in these patients.
